Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20406660 | 0.80 | CYP3A4 (0.40) | KDM4ECNR2MEN1KMT2AALDH1A1 | |
| SCHEMBL18442518 | 0.78 | KDM4E (0.39) | KDM4EGLACNR2MEN1KMT2A | |
| SCHEMBL30999837 | 0.77 | ALDH1A1 (0.53) | KDM4EGLAALDH1A1MAPTL3MBTL1 | |
| SCHEMBL20271484 | 0.74 | EGLN2 (0.35) | KDM4ESSTR4ALDH1A1HTTPTGDR2 | |
| SCHEMBL17315815 | 0.73 | KDM4E (0.38) | KDM4EGLACNR2ALDH1A1MAPT | |
| SCHEMBL17315789 | 0.73 | KDM4E (0.38) | KDM4EKMT2AALDH1A1MAPTHTT | |
| SCHEMBL1124788 | 0.73 | CNR2 (0.44) | KDM4ECNR2KMT2AALDH1A1TSHR | |
| SCHEMBL14932583 | 0.72 | L3MBTL1 (0.41) | KDM4ECNR2MEN1KMT2AALDH1A1 | |
| SCHEMBL15999650 | 0.72 | L3MBTL1 (0.41) | KDM4EMEN1KMT2AALDH1A1GPR35 | |
| SCHEMBL17420749 | 0.71 | MAPT (0.44) | KDM4ESSTR4ALDH1A1MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548903-B2 | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11548903-B2 | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3555106-B1 | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3555106-B1 | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-11021493-B2 | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11021493-B2 | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200231601-A1 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200231601-A1 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200199153-A1 | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2020-06-25 | — | — | US | disclosed |
| US-20200199153-A1 | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2020-06-25 | — | — | US | disclosed |
| EP-3555086-A1 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3555106-A1 | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018112094-A1 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018112084-A1 | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018112094-A1 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199153-A1 | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | KDM4E 4361/4885GLA 38/4885CNR2 1721/4885 |
| US-20200231601-A1 | 1,4-THIAZINE DIOXIDE AND 1,2,4-THIADIAZINE DIOXIDE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | KDM4E 2987/4885GLA 43/4885CNR2 549/4885 |
| US-11021493-B2 | 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use | BACE1, BACE2, APP | KDM4E 2987/4885GLA 43/4885CNR2 549/4885 |
| US-11548903-B2 | Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use | BACE1, BACE2, APP | KDM4E 4361/4885GLA 38/4885CNR2 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.